ticlopidine hydrochloride- ticlopidine hydrochloride tablet, film coated
eon labs, inc. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see box warning and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic anemia - presence of a hemostatic disorder or active
ticlopidine hydrochloride- ticlopidine hydrochloride tablet, film coated
caraco pharmaceutical laboratories, ltd. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - indications and usage: ticlopidine hydrochloride tablets usp are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see boxed warning and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). contraindications: the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic an
ticlopidine hydrochloride tablet, film coated
carilion materials management - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets usp are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. boxed warning warnings - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). clinical trials the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either
teva-ticlopidine tablet
teva canada limited - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors
mylan-ticlopidine tablet
mylan pharmaceuticals ulc - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors
pms-ticlopidine tablet
pharmascience inc - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors
dom-ticlopidine tablet
dominion pharmacal - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors
ticlopidine hydrochloride tablet film coated
apotex corp. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg
ticlopidine teva 250 mg film-coat. tabl.
teva pharma belgium sa-nv - ticlopidine hydrochloride 250 mg - eq. ticlopidine 219,6 mg - film-coated tablet - 250 mg - ticlopidine hydrochloride 250 mg - ticlopidine
ticlopidine tablet
sanis health inc - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors